{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:55Z","timestamp":1792093795471,"version":"4.4.0"},"reference-count":101,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. Pasireotide, a second-generation SRL, shows higher efficacy with respect to both biochemical control and tumor shrinkage but has a worse safety profile. In this review, we discuss the future perspectives of currently available SRLs, focusing on the use of biomarkers of response and precision medicine, new formulations of these SRLs and new drugs, which are under development. Precision medicine, which is based on biomarkers of response to treatment, will help guide the decision-making process by allowing physicians to choose the appropriate drug for each patient and improving response rates. New formulations of available SRLs, such as oral, subcutaneous depot, and nasal octreotide, may improve patients\u2019 adherence to treatment and quality of life since there will be more options available that better suit each patient. Finally, new drugs, such as paltusotine, somatropin, ONO-5788, and ONO-ST-468, may improve treatment adherence and present higher efficacy than currently available drugs.<\/jats:p>","DOI":"10.1210\/clinem\/dgab726","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T19:49:41Z","timestamp":1633636181000},"page":"297-308","source":"Crossref","is-referenced-by-count":75,"title":["The Future of Somatostatin Receptor Ligands in Acromegaly"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-3558","authenticated-orcid":false,"given":"Monica R","family":"Gadelha","sequence":"first","affiliation":[{"name":"Endocrine Unit and Neuroendocrinology Research Center, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-913, Brazil"},{"name":"Neuroendocrine Unit - Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade, Rio de Janeiro, 20231-092, Brazil"},{"name":"Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade, Rio de Janeiro, 20231-092, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Eduardo","family":"Wildemberg","sequence":"additional","affiliation":[{"name":"Endocrine Unit and Neuroendocrinology Research Center, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-913, Brazil"},{"name":"Neuroendocrine Unit - Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade, Rio de Janeiro, 20231-092, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[{"name":"Endocrine Unit and Neuroendocrinology Research Center, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-913, Brazil"},{"name":"Neuroendocrine Unit - Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade, Rio de Janeiro, 20231-092, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"17","key":"2022011806205264100_CIT0001","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1517\/14656566.2013.847090","article-title":"Octreotide for acromegaly treatment: a reappraisal","volume":"14","author":"Giustina","year":"2013","journal-title":"Expert Opin Pharmacother."},{"issue":"9","key":"2022011806205264100_CIT0002","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol."},{"key":"2022011806205264100_CIT0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"2022011806205264100_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"2022011806205264100_CIT0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: from signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front Neuroendocrinol."},{"issue":"12","key":"2022011806205264100_CIT0006","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann Oncol."},{"issue":"11","key":"2022011806205264100_CIT0007","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci."},{"issue":"2","key":"2022011806205264100_CIT0008","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/17446651.2.2.129","article-title":"Octreotide for acromegaly","volume":"2","author":"Cozzi","year":"2007","journal-title":"Expert Rev Endocrinol Metab."},{"issue":"3","key":"2022011806205264100_CIT0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol."},{"issue":"11","key":"2022011806205264100_CIT0010","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2022011806205264100_CIT0011","first-page":"2768","article-title":"Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients\u2013a clinical research center study","volume":"80","author":"Newman","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2022011806205264100_CIT0012","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/archinte.1991.00400080073013","article-title":"Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group","volume":"151","author":"Vance","year":"1991","journal-title":"Arch Intern Med."},{"issue":"5","key":"2022011806205264100_CIT0013","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao","year":"2009","journal-title":"Clin Endocrinol."},{"issue":"3","key":"2022011806205264100_CIT0014","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary."},{"issue":"6","key":"2022011806205264100_CIT0015","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","article-title":"A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly","volume":"66","author":"Mercado","year":"2007","journal-title":"Clin Endocrinol."},{"issue":"5","key":"2022011806205264100_CIT0016","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One."},{"issue":"4","key":"2022011806205264100_CIT0017","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022011806205264100_CIT0018","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1530\/EJE-19-0732","article-title":"The effect of treatment on quality of life in patients with acromegaly: a prospective study","volume":"182","author":"Wolters","year":"2020","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022011806205264100_CIT0019","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev."},{"issue":"8","key":"2022011806205264100_CIT0020","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1210\/jc.2008-2627","article-title":"Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"9 Suppl 2","key":"2022011806205264100_CIT0021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0026-0495(92)90027-8","article-title":"Gallstones during octreotide therapy","volume":"41","author":"Dowling","year":"1992","journal-title":"Metabolism."},{"issue":"2","key":"2022011806205264100_CIT0022","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev."},{"issue":"5","key":"2022011806205264100_CIT0023","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022011806205264100_CIT0024","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-014-0183-4","article-title":"Cabergoline treatment in acromegaly: cons","volume":"46","author":"Kasuki","year":"2014","journal-title":"Endocrine."},{"issue":"6","key":"2022011806205264100_CIT0025","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/cen.13595","article-title":"Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands","volume":"88","author":"Kasuki","year":"2018","journal-title":"Clin Endocrinol."},{"key":"2022011806205264100_CIT0026","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2022011806205264100_CIT0027","first-page":"328","article-title":"Brazilian multicenter study on pegvisomant treatment in acromegaly","volume":"63","author":"Boguszewski","year":"2019","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"2022011806205264100_CIT0028","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022011806205264100_CIT0029","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022011806205264100_CIT0030","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2022011806205264100_CIT0031","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","article-title":"Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study","volume":"62","author":"Shimon","year":"2018","journal-title":"Endocrine."},{"issue":"6","key":"2022011806205264100_CIT0032","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-8587(19)30113-5","article-title":"Potential antitumour activity of pasireotide on pituitary tumours in acromegaly","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"2022011806205264100_CIT0033","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EC-19-0004","article-title":"AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients","volume":"8","author":"Daly","year":"2019","journal-title":"Endocr Connect."},{"issue":"3","key":"2022011806205264100_CIT0034","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000446542","article-title":"Long-term remission of acromegaly after octreotide withdrawal is an uncommon and frequently unsustainable event","volume":"104","author":"Casagrande","year":"2017","journal-title":"Neuroendocrinology."},{"issue":"1","key":"2022011806205264100_CIT0035","first-page":"84","article-title":"Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control","volume":"16","author":"Shimon","year":"2017","journal-title":"Hormones (Athens)."},{"issue":"4","key":"2022011806205264100_CIT0036","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14656566.2016.1146688","article-title":"Pasireotide for the treatment of acromegaly","volume":"17","author":"Wildemberg","year":"2016","journal-title":"Expert Opin Pharmacother."},{"issue":"12","key":"2022011806205264100_CIT0037","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect."},{"issue":"13","key":"2022011806205264100_CIT0038","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40265-016-0615-y","article-title":"Management of hyperglycemia in patients with acromegaly treated with pasireotide LAR","volume":"76","author":"Samson","year":"2016","journal-title":"Drugs."},{"key":"2022011806205264100_CIT0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12797","article-title":"A paradigm shift in the medical treatment of acromegaly: from a \u201ctrial and error\u201d to a personalized therapeutic decision-making process","volume":"83","author":"Gadelha","year":"2015","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2022011806205264100_CIT0040","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"Management of endocrine disease: personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol."},{"key":"2022011806205264100_CIT0041","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coemr.2018.02.001","article-title":"Precision medicine in the medical management of pituitary tumors","volume":"1","author":"Wildemberg","year":"2018","journal-title":"Curr Opinion Endocr Metab Res."},{"issue":"1","key":"2022011806205264100_CIT0042","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.12731","article-title":"Treatment of acromegaly in the era of personalized and predictive medicine","volume":"83","author":"Puig Domingo","year":"2015","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2022011806205264100_CIT0043","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2022011806205264100_CIT0044","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4158\/EP-2018-0500","article-title":"Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline","volume":"25","author":"Ezzat","year":"2019","journal-title":"Endocr Pract."},{"issue":"2","key":"2022011806205264100_CIT0045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3803\/EnM.2020.35.2.206","article-title":"Precision therapy in acromegaly caused by pituitary tumors: how close is it to reality?","volume":"35","author":"Ku","year":"2020","journal-title":"Endocrinol Metab."},{"issue":"7","key":"2022011806205264100_CIT0046","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2022011806205264100_CIT0047","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-016-0768-4","article-title":"Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance","volume":"20","author":"Paragliola","year":"2017","journal-title":"Pituitary."},{"issue":"5","key":"2022011806205264100_CIT0048","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab."},{"issue":"1","key":"2022011806205264100_CIT0049","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.1.02313","article-title":"Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas","volume":"156","author":"Taboada","year":"2007","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022011806205264100_CIT0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022011806205264100_CIT0051","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Invest."},{"issue":"1","key":"2022011806205264100_CIT0052","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022011806205264100_CIT0053","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022011806205264100_CIT0054","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","author":"Fougner","year":"2008","journal-title":"Clin Endocrinol."},{"issue":"6","key":"2022011806205264100_CIT0055","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022011806205264100_CIT0056","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-009-0175-1","article-title":"Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment","volume":"12","author":"Casarini","year":"2009","journal-title":"Pituitary."},{"issue":"3","key":"2022011806205264100_CIT0057","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jcmm.13440","article-title":"Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly","volume":"22","author":"Venegas-Moreno","year":"2018","journal-title":"J Cell Mol Med."},{"key":"2022011806205264100_CIT0058","doi-asserted-by":"crossref","first-page":"9606985","DOI":"10.1155\/2017\/9606985","article-title":"Expression of somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues","volume":"2017","author":"Liu","year":"2017","journal-title":"Int J Endocrinol."},{"issue":"8","key":"2022011806205264100_CIT0059","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1590\/S0004-27302010000800006","article-title":"Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening","volume":"54","author":"Pinho","year":"2010","journal-title":"Arq Bras Endocrinol Metabol."},{"issue":"11","key":"2022011806205264100_CIT0060","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2022011806205264100_CIT0061","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/jcm10071377","article-title":"Genetics of acromegaly and gigantism","volume":"29","author":"Bogus\u0142awska","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"2022011806205264100_CIT0062","doi-asserted-by":"crossref","first-page":"e2271","DOI":"10.1210\/clinem\/dgaa142","article-title":"Clinical MEN-1 among a large cohort of patients with acromegaly","volume":"105","author":"Nachtigall","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2022011806205264100_CIT0063","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1750-1172-6-67","article-title":"Sporadic and genetic forms of paediatric somatotropinoma: a retrospective analysis of seven cases and a review of the literature","volume":"6","author":"Nozi\u00e8res","year":"2011","journal-title":"Orphanet J Rare Dis."},{"issue":"8","key":"2022011806205264100_CIT0064","doi-asserted-by":"crossref","first-page":"E1411","DOI":"10.1210\/jc.2012-1111","article-title":"Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway","volume":"97","author":"Chahal","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022011806205264100_CIT0065","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1530\/ERC-12-0322","article-title":"Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations","volume":"20","author":"Jaffrain-Rea","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2022011806205264100_CIT0066","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2022011806205264100_CIT0067","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11102-018-0876-4","article-title":"Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues","volume":"21","author":"Ozkaya","year":"2018","journal-title":"Pituitary."},{"key":"2022011806205264100_CIT0068","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2022011806205264100_CIT0069","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022011806205264100_CIT0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/eje.1.01935","article-title":"Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly","volume":"153","author":"de Herder","year":"2005","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2022011806205264100_CIT0071","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1530\/eje.1.02073","article-title":"The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly","volume":"154","author":"Pokrajac","year":"2006","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2022011806205264100_CIT0072","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11102-020-01096-2","article-title":"Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly","volume":"24","author":"Swanson","year":"2021","journal-title":"Pituitary."},{"issue":"1","key":"2022011806205264100_CIT0073","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"2022011806205264100_CIT0074","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11102-017-0788-8","article-title":"T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective","volume":"20","author":"Potorac","year":"2017","journal-title":"Pituitary."},{"key":"2022011806205264100_CIT0075","doi-asserted-by":"crossref","first-page":"677919","DOI":"10.3389\/fendo.2021.677919","article-title":"Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective","volume":"12","author":"Nista","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"2022011806205264100_CIT0076","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","article-title":"A structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"2022011806205264100_CIT0077","doi-asserted-by":"crossref","first-page":"dgaa387","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022011806205264100_CIT0078","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/jcmm.16173","article-title":"Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly","volume":"25","author":"Soukup","year":"2021","journal-title":"J Cell Mol Med."},{"key":"2022011806205264100_CIT0079","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","article-title":"A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms","volume":"31","author":"Tuvia","year":"2014","journal-title":"Pharm Res"},{"issue":"7","key":"2022011806205264100_CIT0080","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022011806205264100_CIT0081","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial [published correction appears in J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa637]","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2022011806205264100_CIT0082","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"2022011806205264100_CIT0083","year":"2020"},{"issue":"Suppl 1","key":"2022011806205264100_CIT0084","doi-asserted-by":"crossref","first-page":"A520","DOI":"10.1210\/jendso\/bvab048.1062","article-title":"Improved acromegaly patient satisfaction with oral octreotide capsules compared with injectable somatostatin receptor ligands in the MPOWERED trial","volume":"5","author":"Gordon","year":"2021","journal-title":"J Endocr Soc."},{"issue":"3","key":"2022011806205264100_CIT0085","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"2022011806205264100_CIT0086","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00280-018-3734-1","article-title":"Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study","volume":"83","author":"Pavel","year":"2019","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"2022011806205264100_CIT0087","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord."},{"issue":"9 Suppl 2","key":"2022011806205264100_CIT0088","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0026-0495(92)90035-9","article-title":"Preliminary results with Sandostatin nasal powder in acromegalic patients","volume":"41","author":"Harris","year":"1992","journal-title":"Metabolism."},{"issue":"1","key":"2022011806205264100_CIT0089","first-page":"163","article-title":"A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly","volume":"75","author":"Weeke","year":"1992","journal-title":"J Clin Endocrinol Metab."},{"key":"2022011806205264100_CIT0090","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/14656566.2021.1908998","article-title":"New and emerging pharmacological treatment options for acromegaly","author":"Antunes","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"2022011806205264100_CIT0091","first-page":"SAT","article-title":"SAT-429 final results from the first in man phase 1 clinical trial of CRN00808, an orally bioavailable SST2-selective, nonpeptide somatostatin biased agonist, for the treatment of acromegaly: safety, pharmacokinetics, pharmacodynamics, and midazolam drug interaction in healthy volunteers","volume":"3","author":"Madan","year":"2019","journal-title":"J Endocr Soc"},{"issue":"Suppl 1","key":"2022011806205264100_CIT0092","doi-asserted-by":"crossref","first-page":"A524","DOI":"10.1210\/jendso\/bvab048.1068","article-title":"Pharmacokinetics and safety of an improved oral formulation of paltusotine, a selective, non-peptide somatostatin receptor 2 (SST2) agonist for the treatment of acromegaly","volume":"5","author":"Luo","year":"2021","journal-title":"J Endocr Soc"},{"issue":"Suppl 1","key":"2022011806205264100_CIT0093","doi-asserted-by":"crossref","first-page":"A526","DOI":"10.1210\/jendso\/bvab048.1073","article-title":"Safety and efficacy of switching injected peptide long-acting somatostatin receptor ligands to once daily oral paltusotine: ACROBAT edge phase 2 study","volume":"5","author":"Gadelha","year":"2021","journal-title":"J Endocr Soc"},{"key":"2022011806205264100_CIT0094","year":"2020"},{"issue":"1","key":"2022011806205264100_CIT0095","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/endo.142.1.7880","article-title":"Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin","volume":"142","author":"Afargan","year":"2001","journal-title":"Endocrinology."},{"key":"2022011806205264100_CIT0096","first-page":"GP123","article-title":"A placebo-controlled study to assess the dose-effect of COR-005, a novel somatostatin analogue on plasma glucose regulation compared to octreotide in healthy male subjects","volume":"41","author":"Kutz","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"8","key":"2022011806205264100_CIT0097","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/BF03347512","article-title":"PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion","volume":"27","author":"Shimon","year":"2004","journal-title":"J Endocrinol Invest."},{"issue":"2","key":"2022011806205264100_CIT0098","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1530\/EJE-11-0737","article-title":"DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours","volume":"166","author":"Pl\u00f6ckinger","year":"2012","journal-title":"Eur J Endocrinol."},{"issue":"Suppl 1","key":"2022011806205264100_CIT0099","first-page":"MON","article-title":"MON-464 non-clinical profiling of ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) agonist, to support studies in humans","volume":"3","author":"Komagata","year":"2019","journal-title":"J Endocr Soc."},{"issue":"Suppl 1","key":"2022011806205264100_CIT0100","first-page":"MON","article-title":"MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) agonist, attenuates GH hypersecretion in human GH-secreting, pituitary adenoma-derived cells","volume":"3","author":"Zhou","year":"2019","journal-title":"J Endocr Soc"},{"issue":"Suppl 1","key":"2022011806205264100_CIT0101","first-page":"MON","article-title":"MON-477 Octreotide and ONO-ST-468, a novel and potent somatostatin receptor type-2 (SST2) Agonist, suppress GH hypersecretion in the monkey","volume":"3","author":"Tanaka","year":"2019","journal-title":"J Endocr Soc"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab726\/40854844\/dgab726.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/2\/297\/42224883\/dgab726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/2\/297\/42224883\/dgab726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T01:23:10Z","timestamp":1642468990000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/2\/297\/6383448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":101,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,10,7]]},"published-print":{"date-parts":[[2022,1,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab726","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740948919.793589625","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,10,7]]}}}